These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

509 related articles for article (PubMed ID: 31151293)

  • 1. Development of the Inhibitors that Target the PD-1/PD-L1 Interaction-A Brief Look at Progress on Small Molecules, Peptides and Macrocycles.
    Guzik K; Tomala M; Muszak D; Konieczny M; Hec A; Błaszkiewicz U; Pustuła M; Butera R; Dömling A; Holak TA
    Molecules; 2019 May; 24(11):. PubMed ID: 31151293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy.
    Liu H; Zhao Z; Zhang L; Li Y; Jain A; Barve A; Jin W; Liu Y; Fetse J; Cheng K
    J Immunother Cancer; 2019 Oct; 7(1):270. PubMed ID: 31640814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress in PD-1/PD-L1 pathway inhibitors: From biomacromolecules to small molecules.
    Lin X; Lu X; Luo G; Xiang H
    Eur J Med Chem; 2020 Jan; 186():111876. PubMed ID: 31761384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.
    Wang T; Wu X; Guo C; Zhang K; Xu J; Li Z; Jiang S
    J Med Chem; 2019 Feb; 62(4):1715-1730. PubMed ID: 30247903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insights into non-peptide small-molecule inhibitors of the PD-1/PD-L1 interaction: Development and perspective.
    Wu X; Meng Y; Liu L; Gong G; Zhang H; Hou Y; Liu C; Wu D; Qin M
    Bioorg Med Chem; 2021 Mar; 33():116038. PubMed ID: 33517226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunomodulators targeting the PD-1/PD-L1 protein-protein interaction: From antibodies to small molecules.
    Yang J; Hu L
    Med Res Rev; 2019 Jan; 39(1):265-301. PubMed ID: 30215856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2.
    Zak KM; Grudnik P; Magiera K; Dömling A; Dubin G; Holak TA
    Structure; 2017 Aug; 25(8):1163-1174. PubMed ID: 28768162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advance of peptide-based molecules and nonpeptidic small-molecules modulating PD-1/PD-L1 protein-protein interaction or targeting PD-L1 protein degradation.
    Pan C; Yang H; Lu Y; Hu S; Wu Y; He Q; Dong X
    Eur J Med Chem; 2021 Mar; 213():113170. PubMed ID: 33454550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of Novel Small-Molecule Inhibitors of PD-1/PD-L1 Interaction via Structural Simplification Strategy.
    Zhang H; Xia Y; Yu C; Du H; Liu J; Li H; Huang S; Zhu Q; Xu Y; Zou Y
    Molecules; 2021 Jun; 26(11):. PubMed ID: 34199417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1).
    Zak KM; Grudnik P; Guzik K; Zieba BJ; Musielak B; Dömling A; Dubin G; Holak TA
    Oncotarget; 2016 May; 7(21):30323-35. PubMed ID: 27083005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway.
    Zhan MM; Hu XQ; Liu XX; Ruan BF; Xu J; Liao C
    Drug Discov Today; 2016 Jun; 21(6):1027-36. PubMed ID: 27094104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peptide-based and small synthetic molecule inhibitors on PD-1/PD-L1 pathway: A new choice for immunotherapy?
    Chen T; Li Q; Liu Z; Chen Y; Feng F; Sun H
    Eur J Med Chem; 2019 Jan; 161():378-398. PubMed ID: 30384043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rational design and development of a peptide inhibitor for the PD-1/PD-L1 interaction.
    Boohaker RJ; Sambandam V; Segura I; Miller J; Suto M; Xu B
    Cancer Lett; 2018 Oct; 434():11-21. PubMed ID: 29920293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-1/PD-L1 Inhibitors for Immuno-oncology: From Antibodies to Small Molecules.
    Geng Q; Jiao P; Jin P; Su G; Dong J; Yan B
    Curr Pharm Des; 2018 Feb; 23(39):6033-6041. PubMed ID: 28982322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Stone Guest: How Does pH Affect Binding Properties of PD-1/PD-L1 Inhibitors?
    Riccio A; Coletti A; Dolciami D; Mammoli A; Cerra B; Moretti S; Gioiello A; Ferlin S; Puxeddu E; Macchiarulo A
    ChemMedChem; 2021 Feb; 16(3):568-577. PubMed ID: 33085193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding the structural and energetic basis of PD-1 and monoclonal antibodies bound to PD-L1: A molecular modeling perspective.
    Shi D; Zhou S; Liu X; Zhao C; Liu H; Yao X
    Biochim Biophys Acta Gen Subj; 2018 Mar; 1862(3):576-588. PubMed ID: 29203283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In silico screening and surface plasma resonance-based verification of programmed death 1-targeted peptides.
    Zhang P; Li C; Ji X; Gao M; Lyu S; Dai X; Du J
    Chem Biol Drug Des; 2020 Mar; 95(3):332-342. PubMed ID: 31755641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of protein-protein interactions and hot spot region between PD-1 and PD-L1 by fragment molecular orbital method.
    Lim H; Chun J; Jin X; Kim J; Yoon J; No KT
    Sci Rep; 2019 Nov; 9(1):16727. PubMed ID: 31723178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro assay for the development of small molecule inhibitors targeting PD-1/PD-L1.
    Zhai W; Zhou X; Du J; Gao Y
    Methods Enzymol; 2019; 629():361-381. PubMed ID: 31727249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy.
    Li K; Tian H
    J Drug Target; 2019 Mar; 27(3):244-256. PubMed ID: 29448849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.